Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom

Purpose: To undertake the first substantial clinical study of breast radiotherapy toxicity in BRCA1 and BRCA2 mutation carriers in the United Kingdom. Experimental Design: Acute and late radiation effects were evaluated in a retrospective study of 55 BRCA1 and BRCA2 mutation carriers treated with ra...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2006-12, Vol.12 (23), p.7025-7032
Main Authors: Shanley, Susan, McReynolds, Kate, Ardern-Jones, Audrey, Ahern, Roger, Fernando, Indrajit, Yarnold, John, Evans, Gareth, Eccles, Diana, Hodgson, Shirley, Ashley, Sue, Ashcroft, Linda, Tutt, Andrew, Bancroft, Elizabeth, Short, Susan, Gui, Gerald, Barr, Lester, Baildam, Andrew, Howell, Anthony, Royle, Gavin, Pierce, Lori, Easton, Douglas, Eeles, Rosalind
Format: Article
Language:English
Subjects:
Adult
Aged
BRCA1/2
breast cancer
Breast Neoplasms - diagnosis
Breast Neoplasms - genetics
Breast Neoplasms - therapy
Case-Control Studies
Female
Follow-Up Studies
Genes, BRCA1
Genes, BRCA2
Germ-Line Mutation
Heterozygote
Humans
late toxicity
Middle Aged
mutation carriers
Neoplasm Staging
Radiotherapy
Retrospective Studies
Treatment Outcome
United Kingdom - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: To undertake the first substantial clinical study of breast radiotherapy toxicity in BRCA1 and BRCA2 mutation carriers in the United Kingdom. Experimental Design: Acute and late radiation effects were evaluated in a retrospective study of 55 BRCA1 and BRCA2 mutation carriers treated with radiotherapy for breast cancer at four centers between 1983 and 2002. Individual matching with controls who had sporadic breast cancer was undertaken for age at diagnosis, time since completion of radiation, and treatment variables. Detailed assessments were undertaken by one examiner. Median follow-up was 6.75 years for carriers and 7.75 years for controls. Rates of late events (rib fractures, lung fibrosis, necrosis of soft tissue/bone, and pericarditis) as well as LENT-SOMA scores and clinical photography scores of breast size, shape, and skin telangiectasia were the primary end points. Results: No increase in clinically significant late toxicity was seen in the mutation carriers. Conclusions: These data add substantial weight to the evidence that the outcomes in the treated breast from radiotherapy in women with BRCA1 or BRCA2 mutations are comparable with those in women with sporadic breast cancer.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-06-1244